Mustang Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBIO research report →
About the company
Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
- CEO
- Manuel Litchman
- IPO
- 2017
- Employees
- 4
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $5.33M
- P/E
- -1.68
- P/S
- 0.00
- P/B
- 0.55
- EV/EBITDA
- 4.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -35.38%
- ROIC
- -37.47%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,921,000 · 87.80%
- EPS
- $-0.39 · 84.82%
- Op Income
- $-2,432,000
- FCF YoY
- 53.87%
- 52W High
- $7.00
- 52W Low
- $0.53
- 50D MA
- $0.70
- 200D MA
- $1.02
- Beta
- 2.08
- Avg Volume
- 133.60K
Get TickerSpark's AI analysis on MBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | Litchman Manuel MD | other | 19 |
| Jan 2, 26 | Fortress Biotech, Inc. | other | 278,385 |
| Dec 30, 25 | Herskowitz Neil | sell | 247 |
| Dec 30, 25 | Chill Adam J. | sell | 4 |
| Dec 30, 25 | Jin David | buy | 247 |
| Sep 29, 25 | Fortress Biotech, Inc. | other | 59,334 |
| Apr 24, 25 | Litchman Manuel MD | other | 27 |
| Mar 31, 25 | Fortress Biotech, Inc. | other | 67,806 |
| Dec 31, 24 | Fortress Biotech, Inc. | other | 0 |
| Oct 23, 24 | Jin David | other | 0 |
Our MBIO coverage
Recent articles, reports, and earnings notes.
No research on MBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MBIO report →Similar companies
Peers in the same neighborhood.